Low-dose aspirin linked to 70% lower dementia risk in people with specific genetic profile

A post describes a secondary genetic analysis of the ASPREE trial: Among people in the top 20% for a platelet-count genetic score, 1% on aspirin developed dementia versus 3.3% on placebo. Major bleeding in the same group was 4.4% on aspirin versus 2.1% on placebo. The post notes that the trial found no overall dementia benefit and frames the subgroup finding as a reason for further testing, not advice to start aspirin.